PE20170936A1 - Compuestos novedosos de imidazopiridazina y su uso - Google Patents
Compuestos novedosos de imidazopiridazina y su usoInfo
- Publication number
- PE20170936A1 PE20170936A1 PE2017000461A PE2017000461A PE20170936A1 PE 20170936 A1 PE20170936 A1 PE 20170936A1 PE 2017000461 A PE2017000461 A PE 2017000461A PE 2017000461 A PE2017000461 A PE 2017000461A PE 20170936 A1 PE20170936 A1 PE 20170936A1
- Authority
- PE
- Peru
- Prior art keywords
- heteroaryl
- optionally substituted
- amino
- alkyl
- refers
- Prior art date
Links
- 150000005233 imidazopyridazines Chemical class 0.000 title abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- MKEIRNAFBUSDSC-UHFFFAOYSA-N NC1=NC=NC(=C1C#N)NC(C)C1=CC=2N(N=C1C1=CC=CC=C1)C=CN=2 Chemical compound NC1=NC=NC(=C1C#N)NC(C)C1=CC=2N(N=C1C1=CC=CC=C1)C=CN=2 MKEIRNAFBUSDSC-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se refiere a un derivado de imidazopiridazina de formula (I) en donde Ar es arilo o heteroarilo opcionalmente sustituido; W es heteroarilo o N(R3)heteroarilo opcionalmente sustituido; R1 es H, halo, -CN, entre otros; R2 es H, C1-C6 alquilo o C3-C8 cicloalquilo, opcionalmente sustituidos; R3 es H o C1-C6 alquilo; m es 1 o 2. Es un compuesto seleccionado: 4-amino-6-((1-(6-fenilimidazo[1, 2-b]piridazin-7-il)etil)amino)pirimidina-5-carbonitrilo, entre otros. Tambien se refiere a una composicion que lo comprende. Dicho compuesto es un inhibidor de la enzima fosfatidilinositol-3-cinasa (PI3K), siendo util en el tratamiento de enfermedades inflamatorias, autoinmunitarias o cancer
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410494483.5A CN105503877A (zh) | 2014-09-24 | 2014-09-24 | 咪唑并哒嗪类化合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170936A1 true PE20170936A1 (es) | 2017-07-13 |
Family
ID=55580324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000461A PE20170936A1 (es) | 2014-09-24 | 2015-09-23 | Compuestos novedosos de imidazopiridazina y su uso |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US10208066B2 (es) |
| EP (1) | EP3197898B1 (es) |
| JP (1) | JP6381792B2 (es) |
| KR (2) | KR102111570B1 (es) |
| CN (2) | CN105503877A (es) |
| AR (1) | AR101964A1 (es) |
| AU (1) | AU2015320142B2 (es) |
| BR (1) | BR112017006002B1 (es) |
| CA (1) | CA2958671C (es) |
| CL (1) | CL2017000682A1 (es) |
| CY (1) | CY1122763T1 (es) |
| DK (1) | DK3197898T3 (es) |
| EA (1) | EA032643B1 (es) |
| ES (1) | ES2765510T3 (es) |
| HR (1) | HRP20192279T1 (es) |
| HU (1) | HUE047377T2 (es) |
| IL (1) | IL250703B (es) |
| LT (1) | LT3197898T (es) |
| MX (1) | MX2017003902A (es) |
| MY (1) | MY178136A (es) |
| NZ (1) | NZ729886A (es) |
| PE (1) | PE20170936A1 (es) |
| PH (1) | PH12017500564B1 (es) |
| PL (1) | PL3197898T3 (es) |
| PT (1) | PT3197898T (es) |
| RS (1) | RS59831B1 (es) |
| SG (1) | SG11201701545YA (es) |
| SI (1) | SI3197898T1 (es) |
| SM (1) | SMT201900752T1 (es) |
| TW (1) | TWI707855B (es) |
| UA (1) | UA118066C2 (es) |
| WO (1) | WO2016045591A1 (es) |
| ZA (1) | ZA201701312B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105503877A (zh) * | 2014-09-24 | 2016-04-20 | 和记黄埔医药（上海）有限公司 | 咪唑并哒嗪类化合物及其用途 |
| CN109516973A (zh) * | 2017-09-19 | 2019-03-26 | 南京圣和药业股份有限公司 | 取代嘧啶类化合物、其制备方法及用途 |
| CN110386937A (zh) | 2018-04-20 | 2019-10-29 | 和记黄埔医药（上海）有限公司 | 化合物的晶型和无定型 |
| AR117461A1 (es) | 2018-12-20 | 2021-08-04 | Bayer Ag | Compuestos de heterociclil piridazina como fungicidas |
| CN110028502B (zh) * | 2019-05-29 | 2020-02-14 | 济南周行医药科技有限公司 | 一种激酶抑制剂类药物中间体的制备方法 |
| JP7712932B2 (ja) * | 2019-12-18 | 2025-07-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｌｉｎ２８の阻害剤及びその使用方法 |
| EP4167740A1 (en) | 2020-06-18 | 2023-04-26 | Bayer Aktiengesellschaft | Active compound combinations |
| CN114031558A (zh) * | 2021-12-14 | 2022-02-11 | 无锡捷化医药科技有限公司 | 一种1-(6-氯哒嗪-4-基）乙基-1-酮的制备方法 |
| CN118580191A (zh) * | 2022-01-28 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 用于制备咪唑并[1,2-b]哒嗪类化合物的中间体 |
| WO2025166537A1 (en) * | 2024-02-06 | 2025-08-14 | Epizyme, Inc. | Methods of treatment using an ezh2 modulator |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773958A (en) | 1997-01-03 | 1998-06-30 | Ovonic Battery Company, Inc. | Apparatus for detecting cell reversal in rechargeable batteries |
| AU7079998A (en) * | 1997-04-25 | 1998-11-24 | Takeda Chemical Industries Ltd. | Condensed pyridazine derivatives, their production and use |
| RS55551B1 (sr) | 2004-05-13 | 2017-05-31 | Icos Corp | Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta |
| US8097617B2 (en) | 2006-03-31 | 2012-01-17 | Novartis Ag | Organic compounds |
| AU2007315234A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
| CN101528748A (zh) * | 2006-10-30 | 2009-09-09 | 诺瓦提斯公司 | 作为pi3k脂质激酶抑制剂的咪唑并哒嗪类化合物 |
| EP2079744A1 (en) | 2006-10-30 | 2009-07-22 | Novartis AG | Imidazopyridazines as pi3k lipid kinase inhibitors |
| WO2008138834A1 (en) | 2007-05-09 | 2008-11-20 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| EP2217601A1 (en) | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
| CA2710194C (en) | 2007-12-19 | 2014-04-22 | Amgen Inc. | Inhibitors of p13 kinase |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| WO2010007099A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| CN102271683B (zh) | 2008-11-13 | 2014-07-09 | 吉里德卡利斯托加公司 | 恶性血液病的治疗 |
| JP5808826B2 (ja) * | 2011-02-23 | 2015-11-10 | インテリカイン， エルエルシー | 複素環化合物およびその使用 |
| EP2763994A4 (en) | 2011-10-04 | 2015-08-26 | Gilead Calistoga Llc | NEW QUINOXALINE INHIBITORS OF THE PI3K PATH |
| WO2013082540A1 (en) | 2011-12-02 | 2013-06-06 | Gilead Calistoga Llc | Compositions and methods of treating a proliferative disease with a quinazolinone derivative |
| US20150011569A1 (en) * | 2011-12-15 | 2015-01-08 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| US20140120060A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors |
| US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| TWI574962B (zh) | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| NZ708870A (en) | 2012-12-21 | 2016-09-30 | Gilead Calistoga Llc | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
| CN105503877A (zh) * | 2014-09-24 | 2016-04-20 | 和记黄埔医药（上海）有限公司 | 咪唑并哒嗪类化合物及其用途 |
-
2014
- 2014-09-24 CN CN201410494483.5A patent/CN105503877A/zh active Pending
-
2015
- 2015-09-18 AR ARP150103008A patent/AR101964A1/es active IP Right Grant
- 2015-09-23 KR KR1020197021644A patent/KR102111570B1/ko active Active
- 2015-09-23 MY MYPI2017700637A patent/MY178136A/en unknown
- 2015-09-23 HU HUE15843649A patent/HUE047377T2/hu unknown
- 2015-09-23 KR KR1020177010274A patent/KR102006670B1/ko active Active
- 2015-09-23 CN CN201580047532.3A patent/CN106715432B/zh active Active
- 2015-09-23 SI SI201531035T patent/SI3197898T1/sl unknown
- 2015-09-23 CA CA2958671A patent/CA2958671C/en active Active
- 2015-09-23 EA EA201790276A patent/EA032643B1/ru unknown
- 2015-09-23 HR HRP20192279TT patent/HRP20192279T1/hr unknown
- 2015-09-23 PT PT158436493T patent/PT3197898T/pt unknown
- 2015-09-23 US US15/513,811 patent/US10208066B2/en active Active
- 2015-09-23 UA UAA201703837A patent/UA118066C2/uk unknown
- 2015-09-23 SM SM20190752T patent/SMT201900752T1/it unknown
- 2015-09-23 LT LTEP15843649.3T patent/LT3197898T/lt unknown
- 2015-09-23 ES ES15843649T patent/ES2765510T3/es active Active
- 2015-09-23 BR BR112017006002-7A patent/BR112017006002B1/pt active IP Right Grant
- 2015-09-23 EP EP15843649.3A patent/EP3197898B1/en active Active
- 2015-09-23 DK DK15843649.3T patent/DK3197898T3/da active
- 2015-09-23 RS RS20200012A patent/RS59831B1/sr unknown
- 2015-09-23 SG SG11201701545YA patent/SG11201701545YA/en unknown
- 2015-09-23 AU AU2015320142A patent/AU2015320142B2/en active Active
- 2015-09-23 JP JP2017516139A patent/JP6381792B2/ja active Active
- 2015-09-23 MX MX2017003902A patent/MX2017003902A/es active IP Right Grant
- 2015-09-23 NZ NZ729886A patent/NZ729886A/en not_active IP Right Cessation
- 2015-09-23 WO PCT/CN2015/090367 patent/WO2016045591A1/en not_active Ceased
- 2015-09-23 PE PE2017000461A patent/PE20170936A1/es unknown
- 2015-09-23 PL PL15843649T patent/PL3197898T3/pl unknown
- 2015-09-24 TW TW104131565A patent/TWI707855B/zh active
-
2017
- 2017-02-21 ZA ZA2017/01312A patent/ZA201701312B/en unknown
- 2017-02-21 IL IL250703A patent/IL250703B/en active IP Right Grant
- 2017-03-22 CL CL2017000682A patent/CL2017000682A1/es unknown
- 2017-03-24 PH PH12017500564A patent/PH12017500564B1/en unknown
-
2018
- 2018-12-20 US US16/227,801 patent/US10611777B2/en active Active
-
2020
- 2020-01-08 CY CY20201100013T patent/CY1122763T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170936A1 (es) | Compuestos novedosos de imidazopiridazina y su uso | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| ZA202101788B (en) | Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors | |
| CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| JOP20190142B1 (ar) | مركبات 7-فينيل إيثيل أمينو-4h-بيريميدو[4، 5-d] وبيريدو[4، 3-d]-1، 3-أكسازين-2-ون كمثبطات idh1 وidh2 الطافر | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| MA39172B1 (fr) | Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines | |
| EA201400333A1 (ru) | Бензонитрильные производные в качестве ингибиторов киназ | |
| PE20190395A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| PH12016502504B1 (en) | Mnk inhibitors and methods related thereto | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20161427A1 (es) | Inhibidores heteroarilo de syk | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| PE20211782A1 (es) | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| CL2009000429A1 (es) | Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer. | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| UY32432A (es) | Compuestos de pirimidina fusionada como inhibidores de akt | |
| CL2017002856A1 (es) | Compuestos de tioéter como inhibidores de la nitrificación | |
| CR20140135A (es) | Nuevos derivados de aril-quinolina | |
| UA111198C2 (uk) | Похідні 1-феніл-2-піридинілалкільних спиртів як інгібітори фосфодіестерази | |
| JOP20200081A1 (ar) | أملاح من مشتقات بيرولوتريازين مفيدة بوصفها مثبطات لـ tam |